

# Francesco Barchiesi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7707171/publications.pdf>

Version: 2024-02-01

85  
papers

2,432  
citations

159585

30  
h-index

243625

44  
g-index

87  
all docs

87  
docs citations

87  
times ranked

2978  
citing authors

#	ARTICLE	IF	CITATIONS
1	Experimental Induction of Fluconazole Resistance in <i>Candida tropicalis</i> ATCC 750. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 1578-1584.	3.2	128
2	Effects of Caspofungin against <i>Candida guilliermondii</i> and <i>Candida parapsilosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2719-2727.	3.2	90
3	Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014. <i>Infection</i> , 2016, 44, 205-213.	4.7	81
4	In Vitro Activities of the New Antifungal Triazole SCH 56592 against Common and Emerging Yeast Pathogens. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 226-229.	3.2	75
5	Interactions between Triazoles and Amphotericin B against <i>Cryptococcus neoformans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 2435-2441.	3.2	75
6	Invasive aspergillosis in liver transplant recipients: Epidemiology, clinical characteristics, treatment, and outcomes in 116 cases. <i>Liver Transplantation</i> , 2015, 21, 204-212.	2.4	72
7	Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study). <i>Clinical Microbiology and Infection</i> , 2020, 26, 1545-1553.	6.0	71
8	In-vitro activity and killing effect of polycationic peptides on methicillin-resistant <i>Staphylococcus aureus</i> and interactions with clinically used antibiotics. <i>Diagnostic Microbiology and Infectious Disease</i> , 2000, 38, 115-118.	1.8	70
9	<i>Candida guilliermondii</i> Fungemia in Patients with Hematologic Malignancies. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2458-2464.	3.9	64
10	Candidemia in the elderly: What does it change?. <i>PLoS ONE</i> , 2017, 12, e0176576.	2.5	59
11	Antimicrobial activity of polycationic peptides. <i>Peptides</i> , 1999, 20, 1265-1273.	2.4	55
12	Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study. <i>Clinical Microbiology and Infection</i> , 2021, 27, 105-111.	6.0	55
13	In Vitro Activity of Posaconazole against Clinical Isolates of Dermatophytes. <i>Journal of Clinical Microbiology</i> , 2001, 39, 4208-4209.	3.9	53
14	Inhibition of growth of <i>Pneumocystis carinii</i> by lactoferrins alone and in combination with pyrimethamine, clarithromycin and minocycline. <i>Journal of Antimicrobial Chemotherapy</i> , 2000, 46, 577-582.	3.0	50
15	Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia. <i>JAMA Network Open</i> , 2021, 4, e2136246.	5.9	50
16	Statistical Analyses of Correlation between Fluconazole MICs for <i>Candida</i> spp. Assessed by Standard Methods Set Forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). <i>Journal of Clinical Microbiology</i> , 2007, 45, 109-111.	3.9	49
17	Cefiderocol treatment for carbapenem-resistant <i>Acinetobacter baumannii</i> infection in the ICU during the COVID-19 pandemic: a multicentre cohort study. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab174.	2.1	48
18	Evaluation of the E test system versus a microtitre broth method for antifungal susceptibility testing of yeasts against fluconazole and itraconazole. <i>Journal of Antimicrobial Chemotherapy</i> , 1995, 36, 93-100.	3.0	43

#	ARTICLE	IF	CITATIONS
19	Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 50, 999-1002.	3.0	43
20	Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3359-3365.	3.0	41
21	Comparison of the Fungicidal Activities of Caspofungin and Amphotericin B against <i>Candida glabrata</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4989-4992.	3.2	39
22	Factors related to outcome of bloodstream infections due to <i>Candida parapsilosis</i> complex. <i>BMC Infectious Diseases</i> , 2016, 16, 387.	2.9	38
23	Interactions of Posaconazole and Flucytosine against <i>Cryptococcus neoformans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1355-1359.	3.2	37
24	Activity of the new antifungal triazole, posaconazole, against <i>Cryptococcus neoformans</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2001, 48, 769-773.	3.0	37
25	Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1807-1819.	3.0	37
26	Candidemia: Evolution of Drug Resistance and Novel Therapeutic Approaches. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 5543-5553.	2.7	37
27	Epidemiology and outcome of systemic infections due to <i>saprochaete capitata</i> : case report and review of the literature. <i>Infection</i> , 2015, 43, 211-215.	4.7	36
28	Posaconazole Prophylaxis in Experimental Systemic Zygomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 73-77.	3.2	35
29	Voriconazole and multidrug resistance in <i>Candida albicans</i> . <i>Mycoses</i> , 2007, 50, 109-115.	4.0	35
30	Caspofungin in Combination with Amphotericin B against <i>Candida parapsilosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 941-945.	3.2	33
31	In Vitro Activities of Voriconazole in Combination with Three Other Antifungal Agents against <i>Candida glabrata</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3317-3322.	3.2	30
32	Comparative Effects of Micafungin, Caspofungin, and Anidulafungin against a Difficult-To-Treat Fungal Opportunistic Pathogen, <i>Candida glabrata</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1215-1222.	3.2	30
33	Posaconazole and Amphotericin B Combination Therapy against <i>Cryptococcus neoformans</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3312-3316.	3.2	29
34	In-vitro interactions of itraconazole with flucytosine against clinical isolates of <i>Cryptococcus neoformans</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 44, 65-70.	3.0	28
35	Bloodstream infections in the COVID-19 era: results from an Italian multi-centre study. <i>International Journal of Infectious Diseases</i> , 2021, 111, 31-36.	3.3	28
36	In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2158-2163.	3.0	27

#	ARTICLE	IF	CITATIONS
37	In vitro and in vivo effects of echinocandins against <i>Candida parapsilosis sensu stricto</i> , <i>Candida orthopsilosis</i> and <i>Candida metapsilosis</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2195-2202.	3.0	27
38	In-vitro activity of polycationic peptides against <i>Cryptosporidium parvum</i> , <i>Pneumocystis carinii</i> and yeast clinical isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 44, 403-406.	3.0	26
39	In vitrosusceptibility of dermatophytes to conventional and alternative antifungal agents. <i>Medical Mycology</i> , 2009, 47, 321-326.	0.7	26
40	Turbidimetric and visual criteria for determining the in vitro activity of six antifungal agents against <i>Candida</i> spp. and <i>Cryptococcus neoformans</i> . <i>Mycopathologia</i> , 1993, 124, 19-25.	3.1	25
41	Electrophoretic karyotype and in vitro antifungal susceptibility of <i>Cryptococcus neoformans</i> isolates from AIDS patients. <i>Diagnostic Microbiology and Infectious Disease</i> , 1995, 23, 99-103.	1.8	25
42	High Rate of Ceftobiprole Resistance among Clinical Methicillin-Resistant <i>Staphylococcus aureus</i> Isolates from a Hospital in Central Italy. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	25
43	Carbapenem-Resistant <i>Klebsiella pneumoniae</i> influences the outcome of early infections in liver transplant recipients. <i>BMC Infectious Diseases</i> , 2016, 16, 538.	2.9	24
44	Caspofungin in Combination with Amphotericin B against <i>Candida glabrata</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2546-2549.	3.2	23
45	Clinical characteristics, management and health related quality of life in young to middle age adults with COVID-19. <i>BMC Infectious Diseases</i> , 2021, 21, 134.	2.9	23
46	In vitro activity of five antifungal agents against clinical isolates of <i>Saccharomyces cerevisiae</i> . <i>Medical Mycology</i> , 1998, 36, 437-440.	0.7	21
47	Clinical and epidemiological characteristics of KPC-producing <i>Klebsiella pneumoniae</i> from bloodstream infections in a tertiary referral center in Italy. <i>BMC Infectious Diseases</i> , 2019, 19, 611.	2.9	20
48	Short-Term Exposure to Membrane-Active Antibiotics Inhibits <i>Cryptosporidium parvum</i> Infection in Cell Culture. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 3473-3475.	3.2	18
49	Comparison between Disk Diffusion and Microdilution Methods for Determining Susceptibility of Clinical Fungal Isolates to Caspofungin. <i>Journal of Clinical Microbiology</i> , 2007, 45, 3529-3533.	3.9	18
50	In-vitro activity of dicationic aromatic compounds and fluconazole against <i>Cryptococcus neoformans</i> and <i>Candida</i> spp.. <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 44, 223-228.	3.0	17
51	Comparison of Three Methods for Testing Azole Susceptibilities of <i>Candida albicans</i> Strains Isolated Sequentially from Oral Cavities of AIDS Patients. <i>Journal of Clinical Microbiology</i> , 1998, 36, 1578-1583.	3.9	17
52	In vitro activity of the synthetic lipopeptide PAL-Lys-Lys-NH <sub>2</sub> alone and in combination with antifungal agents against clinical isolates of <i>Cryptococcus neoformans</i> . <i>Peptides</i> , 2007, 28, 1509-1513.	2.4	16
53	In vitro activity of the protegrin <i>IB367</i> alone and in combination compared with conventional antifungal agents against dermatophytes. <i>Mycoses</i> , 2014, 57, 233-239.	4.0	15
54	Effect of pentamidine on the growth of <i>Cryptococcus neoformans</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 1994, 33, 1229-1232.	3.0	14

#	ARTICLE	IF	CITATIONS
55	Posaconazole against <i>Candida glabrata</i> Isolates with Various Susceptibilities to Fluconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1929-1933.	3.2	14
56	Anidulafungin in Combination with Amphotericin B against <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4035-4039.	3.2	14
57	Disruption of Homocitrate Synthase Genes in <i>Candida albicans</i> Affects Growth But Not Virulence. <i>Mycopathologia</i> , 2010, 170, 397-402.	3.1	13
58	Effects of amphotericin B on <i>Aspergillus flavus</i> clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2587-2591.	3.0	13
59	Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2230-2233.	3.0	13
60	Efficacy of Caspofungin against <i>Aspergillus terreus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 5133-5135.	3.2	12
61	Candidemia in intensive care units over nine years at a large Italian university hospital: Comparison with other wards. <i>PLoS ONE</i> , 2021, 16, e0252165.	2.5	12
62	Comparison of four methods for DNA typing of clinical isolates of <i>Candida glabrata</i> . <i>Journal of Medical Microbiology</i> , 1999, 48, 955-963.	1.8	11
63	Changing characteristics and risk factors of patients with and without incident HCV infection among HIV-infected individuals. <i>Infection</i> , 2013, 41, 987-990.	4.7	11
64	Estimated burden of fungal infections in Italy. <i>Journal of Infection</i> , 2018, 76, 103-106.	3.3	11
65	In vitro activity of synthetic antimicrobial peptides against <i>Candida</i> . <i>Polish Journal of Microbiology</i> , 2006, 55, 303-7.	1.7	10
66	Candidemia in Internal Medicine: Facing the New Challenge. <i>Mycopathologia</i> , 2022, 187, 181-188.	3.1	10
67	Posaconazole Activity against <i>Candida glabrata</i> after Exposure to Caspofungin or Amphotericin B. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 513-517.	3.2	9
68	Evaluating Liver Fibrosis by Transient Elastometry in Patients With HIV-HCV Coinfection and Mono-infection. <i>Hepatitis Monthly</i> , 2014, 14, e15426.	0.2	9
69	Antifungal susceptibility patterns of yeast isolates causing bloodstream infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 431-433.	3.0	8
70	Sequential Therapy with Caspofungin and Fluconazole for <i>Candida albicans</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4056-4058.	3.2	8
71	Tolerance to amphotericin B in clinical isolates of <i>Candida tropicalis</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2004, 50, 179-185.	1.8	8
72	Characterisation of candidemia in patients with recent surgery: A 7-year experience. <i>Mycoses</i> , 2019, 62, 1056-1063.	4.0	8

#	ARTICLE	IF	CITATIONS
73	Evaluation of the Disk Diffusion Method Compared to the Microdilution Method in Susceptibility Testing of Anidulafungin against Filamentous Fungi. <i>Journal of Clinical Microbiology</i> , 2008, 46, 4071-4074.	3.9	7
74	Fungicidal activity and PK/PD of caspofungin as tools to guide antifungal therapy in a fluconazole-resistant <i>C. parapsilosis</i> candidemia. <i>Journal of Chemotherapy</i> , 2017, 29, 376-379.	1.5	6
75	Intestinal parasitosis: data analysis 2006-2011 in a teaching hospital of Ancona, Italy. <i>Infezioni in Medicina</i> , 2013, 21, 34-9.	1.1	6
76	In vitro and in vivo anticytotoxic activities of a new pyrazolo-isothiazole derivative. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 167-170.	3.0	5
77	Species distribution and antifungal susceptibilities of bloodstream <i>Candida</i> isolates: a nine-years single center survey. <i>Journal of Chemotherapy</i> , 2020, 32, 244-250.	1.5	5
78	Ceftazidime-avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study. <i>Antibiotics</i> , 2022, 11, 321.	3.7	5
79	In-vitro activity of rifabutin and albendazole singly and in combination with other clinically used antimicrobial agents against <i>Pneumocystis carinii</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 44, 653-659.	3.0	3
80	In vitro effect of short-term exposure to two synthetic peptides, alone or in combination with clarithromycin or rifabutin, on <i>Cryptosporidium parvum</i> infectivity. <i>Peptides</i> , 2002, 23, 1015-1018.	2.4	3
81	Comparison of liver fibrosis progression in HIV/HCV co-infected and HCV mono-infected patients by transient elastometry. <i>Scandinavian Journal of Infectious Diseases</i> , 2014, 46, 797-802.	1.5	3
82	Central venous catheter unrelated candidemia influences the outcome of infection in patients with solid tumors. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 1499-1505.	2.9	3
83	Prevalence and predictors of malignancies in a polycentric cohort of HIV patients from Italy. <i>Journal of the International AIDS Society</i> , 2014, 17, 19652.	3.0	2
84	Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU: authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1651-1652.	3.0	1
85	Prevalence and predictors of malignancies in HIV patients: results of a retrospective multicentric Italian cohort. <i>Infezioni in Medicina</i> , 2019, 27, 53-57.	1.1	1